ARHGAP28: A Potential Drug Target and Biomarker for G protein-Coupled Signaling

Target Name: ARHGAP28

NCBI ID: G79822

ARHGAP28

ARHGAP28: A Potential Drug Target and Biomarker for G protein-Coupled Signaling

G protein-coupled signaling (GCS) is a widely recognized signaling pathway that plays a crucial role in cellular processes such as cell survival, migration, and regulation of cellular signaling pathways. The ARHGAP28 protein is a non-protein kinase GTPase-activating protein (GAP) that is expressed in various cell types and is involved in the regulation of GCS signaling pathways.

ARHGAP28 is a 28kDa protein that is expressed in various tissues, including brain, heart, and muscle. It is a critical protein that is involved in the regulation of cellular signaling pathways, including the GCS pathway. The GCS pathway is a complex signaling pathway that involves the interaction between various protein kinases and GAPs. ARHGAP28 is one of the key proteins that is involved in this pathway.

The GCS pathway is involved in the regulation of various cellular processes, including cell survival, apoptosis, angiogenesis, and inflammation. The pathway is activated by various factors, including growth factors, stress signals, and chemokines. The ARHGAP28 protein is involved in the regulation of this pathway by activating the GAP activity of the protein.

ARHGAP28 is a critical protein that is involved in the regulation of cellular signaling pathways. It is a GAP that can activate the GCS pathway by interacting with the protein S/T kinase. S/T kinase is a protein that is involved in the regulation of cellular signaling pathways, including the GCS pathway. The interaction between ARHGAP28 and S/T kinase allows for the regulation of the GCS pathway by ARHGAP28.

ARHGAP28 is also involved in the regulation of the degradation of other proteins, including the protein p21. p21 is a tumor suppressor protein that is involved in the regulation of cell cycle growth and apoptosis. The degradation of p21 by ARHGAP28 is critical for the regulation of cell cycle growth and the regulation of apoptosis.

In addition to its role in the regulation of GCS signaling pathways, ARHGAP28 is also involved in the regulation of cellular signaling pathways that are independent of the GCS pathway. For example, ARHGAP28 is involved in the regulation of the signaling pathway that is involved in the regulation of cell adhesion. The regulation of cell adhesion by ARHGAP28 is critical for the regulation of cellular interactions and the development of tissues.

ARHGAP28 is also involved in the regulation of cellular signaling pathways that are involved in the regulation of ion channels. The regulation of ion channels by ARHGAP28 is critical for the regulation of the conductivity of cells and the regulation of electrical signals.

In conclusion, ARHGAP28 is a critical protein that is involved in the regulation of various cellular signaling pathways, including the GCS pathway. Its role in the regulation of these pathways makes it a potential drug target and biomarker for various diseases. Further research is needed to fully understand the role of ARHGAP28 in cellular signaling pathways and its potential as a drug target.

Protein Name: Rho GTPase Activating Protein 28

Functions: GTPase activator for the Rho-type GTPases by converting them to an inactive GDP-bound state

The "ARHGAP28 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARHGAP28 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets